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Plasminogen activator inhibitor-1 (PAI-1), a serpin, is
the physiological inhibitor of tissue-type and uroki-
nase-type plasminogen activators and thus also an
inhibitor of fibrinolysis and tissue remodeling. It is
a potential therapeutic target in many pathological
conditions, including thrombosis and cancer.
Several types of PAI-1 antagonist have been devel-
oped, but the structural basis for their action has re-
mained largely unknown. Here we report X-ray
crystal structure analysis of PAI-1 in complex with
a small-molecule antagonist, embelin. We propose
a mechanism for embelin-induced rapid conversion
of PAI-1 into a substrate for its target proteases
and the subsequent slow conversion of PAI-1 into
an irreversibly inactivated form. Our work provides
structural clues to an understanding of PAI-1 inacti-
vation by small-molecule antagonists and an impor-
tant step toward the design of drugs targeting PAI-1.
INTRODUCTION
Plasminogen activator inhibitor-1 (PAI-1) is the primary physio-
logical inhibitor of tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA). In the circulation
and in the pericellular space, it is associated with its Mr
70,000 cofactor vitronectin. The PAI-1/plasminogen-activator
complexes are cleared from the circulation and the pericellular
space by binding to endocytosis receptors of the low-density
lipoprotein receptor family, including low-density-lipoprotein-
receptor-associated protein and very-low-density lipoprotein
receptor (for reviews, see Dupont et al., 2009; Gliemann et al.,
1994).
The relative plasma levels of tPA and PAI-1 determine the
fibrinolytic capacity of blood (for a review, see Booth, 1999). In
humans, a high plasma PAI-1 level is a risk factor in thromboticChemistry & Biology 20, 253disease. Conditions with an increased risk of thrombosis, i.e.,
obesity, hypertension, and type-2 diabetes are associated with
elevated plasma PAI-1 levels (for reviews, see Booth, 1999;
Vaughan, 2002). Evidence for a direct causal role of PAI-1 in
thrombotic events comes from the observation that transgenic
mice overexpressing PAI-1 develop thrombosis (Eren et al.,
2002; Erickson et al., 1990), whereas removal of PAI-1 activity
by gene deletion (Carmeliet et al., 1993) or antagonizing anti-
bodies (Abrahamsson et al., 1996; van Giezen et al., 1997)
prevents thrombus formation. In human malignant tumors, the
levels of uPA and PAI-1 are significantly higher than those in
the corresponding normal tissues. Moreover, tumor levels of
uPA and PAI-1 are currently recognized as the most extensively
validated biological prognostic factors in breast cancer (Harris
et al., 2007; Ja¨nicke et al., 2001; Look et al., 2002) and as
markers of a poor prognosis in other cancers (Duffy, 2002).
Based on these findings, PAI-1 is a potential therapeutic target
in several pathological conditions. During the past decades,
many efforts have therefore been made to develop PAI-1 antag-
onists in the form of small molecules (Bjo¨rquist et al., 1998;
Cale et al., 2010; Charlton et al., 1996; Crandall et al., 2004;
Egelund et al., 2001; Einholm et al., 2003; Elokdah et al., 2004;
Friederich et al., 1997; Gardell et al., 2007; Gils et al., 2002;
Gorlatova et al., 2007; Izuhara et al., 2008; Liang et al., 2005;
Neve et al., 1999; Rupin et al., 2008), monoclonal antibodies
(Nielsen et al., 1986; for a review, see Gils and Declerck, 2004),
peptides (Jensen et al., 2006; Mathiasen et al., 2008), and RNA
aptamers (Blake et al., 2009;Madsen et al., 2010). Several antag-
onists were shown to function in vivo. For example, the small-
molecule PAI-1 antagonist XR5118 (half-maximal inhibitory
concentration [IC50]3.5 mM) promoted endogenous fibrinolysis
and reduced postthrombolysis thrombus growth in rabbits
(Friederich et al., 1997), and the small-molecule PAI-1 antagonist
PAI-039 (tiplaxtinin, IC502.7 mM) had in vivo oral efficacy in two
different models of acute arterial thrombosis (Elokdah et al.,
2004). Although several of these candidate compounds show
promising characteristics in the laboratory, to the best of our
knowledge, no PAI-1 antagonist has yet been evaluated in
clinical trials.–261, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 253






1.62 ± 0.16a 4.94 ± 1.04
Emb-d1
1.04 ± 0.13 8.20 ± 2.70
Emb-d2
1.96 ± 0.25 3.87 ± 0.33
aIC50 mean value(mM) ± standard deviation, based on at least three inde-
pendent experiments.
See also Figures S2–S4.
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Discovery and Structural Basis of PAI-1 InhibitorPAI-1 belongs to the serpin family, which includesmany serine
protease inhibitors and whose members share a common fold
with features including three b strands, nine a helixes, and a
flexible reactive center loop (RCL). PAI-1 inhibits its target
proteases following the classical serpin mechanism of protease
inhibition: (1) the RCL inserts into the active site of the target
proteases and a reversible Michaelis complex is formed; (2) the
RCL is cleaved by the target protease, leading to formation of
an acyl-enzyme intermediate, in which the P1 residue of the
RCL is covalently bound to the active-site serine of the protease
by an ester bond; (3) the N-terminal side of the RCL rapidly
inserts into b sheet A, thereby dragging the protease to the
opposite pole of the serpin; and (4) the active site of the protease
is distortedand theP1 residuepulledout of the specificity pocket,
preventing hydrolysis of the ester bond. Under some conditions,
complex formation is abortive and the P1-P10 bond is cleaved
without complex formation, an event termed serpin substrate
behavior. Under physiological conditions, active PAI-1 can spon-
taneously convert into an inactive, so-called latent form with
a half-life of 1–2 hr in which the RCL fully inserts into b sheet A
without prior cleavage (Levin and Santell, 1987). Structurally,
thus, PAI-1 can exist in three different conformations, i.e., the
active form, the latent form, and the cleaved form, in which the
RCL is cleaved and inserted into b sheet A either in complex
with a target protease or as a free substrate-cleaved product
(for reviews, see Dupont et al., 2009; Huntington, 2006).
Until now, structural information about the mechanism of
action of small-molecule PAI-1 antagonists has been lacking.
The structural metastability of PAI-1, together with its propensity
to form aggregates (Lin et al., 2011), poses challenges to
X-ray crystal structure analyses of PAI-1 in complex with PAI-1
antagonists. Isolation from a library of natural products of
small-molecule PAI-1 antagonist, embelin, has allowed us to
determine the three-dimensional structure of PAI-1 in complex
with a small-molecule antagonist. We have shown that embelin
abolishes the inhibitory action of PAI-1 by a mechanism
similar to that previously described by biochemical methods254 Chemistry & Biology 20, 253–261, February 21, 2013 ª2013 Elsefor a group of negatively charged amphipathic small-molecule
inhibitors of PAI-1 (Egelund et al., 2001). Our work provides
structural information about the mechanism behind such
antagonists.
RESULTS
Identification of a PAI-1 Antagonist: Embelin
In order to identify small-molecule PAI-1 antagonists, we
adopted a chromogenic assay in which the activity of PAI-1
was evaluated by its ability to inhibit uPA-mediated hydrolysis
of chromogenic substrates. By screening of a natural product
library containing 1,600 compounds, we found a small-molecule
compound, embelin (Table 1), which inhibits wild-type (WT)
PAI-1 with an IC50 value of 1.6 mM. A stabilized variant of PAI-1
(N150H-K154T-Q319L-M354I) termed 14-1B (Berkenpas et al.,
1995), which was required for the subsequent crystallization
trials, was inhibited with an IC50 value of about 5 mM (Table 1).
Similar results were obtained with tPA as the target protease
(Figure S1 available online). To evaluate which part of the
chemical structure of embelin is important for its antagonistic
action, we tested two available structurally related compounds,
Emb-d1 and Emb-d2 (Table 1). In support of a similar mode of
binding, all three compounds inhibited WT and 14-1B PAI-1
with IC50 values between 1 and 10 mM (Table 1). By comparison
of the chemical structures, it is evident that the composition of
the aliphatic chain conjugated to the polar aromatic-ring struc-
ture (head group) is of limited importance for the IC50 values.
To investigate the target specificity of embelin and the related
compounds, we examined their effects on two other serpins,
namely protease nexin-1 (PN-1), which is PAI-1’s closest phylo-
genetic relative, and PAI-2. Both serpins are relatively fast
inhibitors of uPA (Kruithof et al., 1995). The IC50 value for the
embelin-induced inactivation of either PAI-2 or PN-1 was more
than 40-fold that for WT PAI-1 (Figure S2).
Using PAI-1 in physiologically relevant concentrations, embe-
lin was shown to antagonize PAI-1 inhibition of uPA-catalyzed
generation of plasmin in a coupled assay (Figure S3). However,
preincubation of PAI-1 with 5 mM somatomedin B-domain of
the PAI-1 cofactor vitronectin (Seiffert and Loskutoff, 1991;
Zhou et al., 2003) before the addition of embelin abolished the
inhibition of embelin against PAI-1, suggesting that SMB blocks
the binding of embelin to PAI-1 (Figure S4).
Embelin-PAI-1 Binding Affinity
We next used perturbation of intrinsic tryptophan fluorescence
to study the binding of embelin to various conformational forms
of PAI-1. This tryptophan-fluorescence-quenching method was
originally developed to measure the binding of antagonists to
PAI-1 (Madsen et al., 2010). To be able to work with a pure
preparation of active PAI-1 without contamination with latent
material, we used PAI-1-14-1B for this analysis. Figure 1 shows
the change of tryptophan fluorescence emission of 10 mM active
PAI-1-14-1B at 328 nm when titrated with the indicated final
concentrations of embelin at 25C. The experimental data from
at least three independent measurements were fitted to a 1:1
binding model, resulting in a KD of 24 mM, a value only slightly
higher than the IC50 value for inhibition of PAI-1-14-1B by
embelin (Table 1). This result also suggests that embelin bindsvier Ltd All rights reserved
Figure 1. Binding of Embelin to PAI-1
Perturbation of intrinsic tryptophan fluorescence of active PAI-1-14-1B
(solid circles), reactive-center-cleaved PAI-1-14-1B (open circles), or latent
WT PAI-1 (triangles) at 328 nm was monitored after addition of the indicated
concentrations of embelin. The fluorescence emission values were corrected
for PAI-1 fluorescence and embelin interfilter effects and normalized to Fmax. A
KD of 24 ± 4 mM (n = 3) for binding of embelin to PAI-1-14-1B was obtained,
based on a best fit (solid line) to a 1:1 binding model. Each of the plots in the
figure represents one representative experiment out of three independent
determinations.
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fluorescence. When evaluating the binding of embelin to latent
WT PAI-1 and reactive-center-cleaved PAI-1-14-1B, no satu-
rable binding could be observed and it could be concluded
that the binding affinities were at least 10-fold lower than that
for binding to active PAI-1-14-1B (Figure 1).
Embelin’s Antagonistic Mechanism
To study embelin’s antagonistic mechanism, 0.4 mM PAI-1 was
preincubated with 20 mM embelin for different lengths of time,
followed by addition of 4 mM uPA and evaluation of uPA:PAI-1
complex formation by SDS-PAGE. As shown in Figure 2, in the
absence of embelin, more than 90% of the PAI-1 was able to
form a covalent complex with uPA, as indicated by the appear-
ance of a band with amigration corresponding to aMr of approx-
imately 70,000.When PAI-1 was pre-incubated with embelin, the
intensity of the complex band was reduced in a time-dependent
manner. Concomitantly, at short incubation times, there was an
increase in the density of a band migrating slightly faster than
native PAI-1, representing the reactive-center-loop-cleaved
form (Jensen and Gettins, 2008) (Figure 2). At later time points,
PAI-1 reappeared at the position of the native band, representing
a nonreactive, noncleaved species. This pattern was observed
for both WT and PAI-1-14-1B, although PAI-1-14-1B was inacti-
vatedmore slowly by embelin. At 37C,WT PAI-1 was converted
to substrate behavior within a couple of minutes, after which time
the irreversibly inactivated nonreactive form began to accumu-
late, although the conversion to this form was not complete
until after more than 60 min (Figure 2A). This inactivated form
of PAI-1 was found to be PAI-1 oligomer. The inactivation rate
decreased strongly with decreasing temperature. At 4C, there
was little conversion to the irreversibly inactivated, inert form
within several hours (Figure 2B). These observations closely
follow those described in previous reports, in which it was shown
that a group of negatively charged small-molecule PAI-1 antag-
onists induces a rapid reversible conversion of PAI-1 into a formChemistry & Biology 20, 253exhibiting substrate behavior, resulting in a slightly faster migra-
tion in SDS-PAGE, and subsequently, a slower irreversibly
inactivated form, which causes PAI-1 to appear as a nonreactive
band in SDS-PAGE (Egelund et al., 2001).
Additional support for the link between the embelin-induced
PAI-1 inhibition and the previously published mechanism was
obtained by an assay based on a chromogenic uPA substrate.
In the assay, PAI-1 was incubated with 20 mMembelin for varying
periods of time, followed by assay of the remaining PAI-1 activity
by a chromogenic assay in buffers with or without 0.5% bovine
serum albumin (BSA). Serum albumin binds to embelin and
prevents the effect of embelin on PAI-1; thus, reversibly inacti-
vated PAI-1 will regain activity in the assay with BSA, but not in
the assay without BSA, while irreversibly inactivated PAI-1 will
remain inactive in both assays. When comparing the time
courses of embelin inactivation of PAI-1 in the two assays, it is
evident that the inactivation at early time points is reversible,
while at later time points the slower irreversible inactivation of
PAI-1 is increasingly dominant (Figure 3).
X-Ray Crystal Structure Analysis of PAI-1 in Complex
with Embelin
As embelin appears to represent a previously described group of
small-molecule antagonists of PAI-1, we decided to pursue
a structural understanding of its antagonism of PAI-1. To do
so, we subjected the embelin-PAI-1 complex to X-ray crystal
structure analysis.
As crystallization of active PAI-1 is hampered by its tendency
to aggregate and its short shelf life due to conversion to the latent
form, and high salt and low pH conditions are typically needed to
keep PAI-1 stable in vitro (Stout et al., 2000; Zhou et al., 2001),
we decided to use functionally stabilized PAI-1-14-1B, which
has been commonly used in crystallographic studies (Lin et al.,
2011; Nar et al., 2000; Sharp et al., 1999; Stout et al., 2000).
Following extensive trials with different approaches, we found
that PAI-1 remains stably in solution in the presence of embelin,
especially at low temperature (4C), which allows dialysis of
the protein to low salt (150 mM NaCl) and neutral pH (pH 7.4),
and at this condition, we finally succeeded in cocrystallizing
embelin with active PAI-1-14-1B. A 2.6 A˚ data set was collected
and initial phasing was obtained by molecular replacement
using existing PAI-1 structure (Protein Data Bank [PDB] 1B3K).
Statistics of the data collection and structure refinement are
summarized in Table S1.
The asymmetric unit contained four PAI-1 molecules, each
bearing the well described fold of an inhibitory active serpin.
As for themajority of crystallized active serpins, the RCL appears
fully flexible and solvent exposed and thus, for the most part,
unobservable. In two of the four molecules (molecules A and
C) in the asymmetric unit, parts of the RCL showed visible
electron density due to crystal lattice contacts with neighboring
molecules at their b sheet A, leading to the extension of the
b sheet A of the contacted molecule with a seventh strand.
Alignment of all four PAI-1 molecules together with the previ-
ously published structure of free PAI-1-14-1B (Stout et al.,
2000) showed that none of the four molecules deviated signifi-
cantly from the others with respect to overall fold (RMSD
between 0.40 and 0.57 A˚; high values include embelin). Thus,
effects caused by embelin binding to PAI-1 seem to result from–261, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 255
Figure 2. Time Course of Inactivation of
PAI-1 by Embelin, as Evaluated by SDS-
PAGE
PAI-1WT or PAI-1 14-1B, at both 37C (A) and 4C
(B), in both cases 478 nM, were incubated in the
presence of 24.5 mMembelin. At the indicated time
points, samples of the incubation mixtures were
mixed with a small volume of uPA, resulting in final
concentrations of 0.4 mM PAI-1, 20mM embelin,
and 4 mMuPA. After 2 min, SDS sample buffer was
added to the samples, which were then subjected
to reducing SDS-PAGE. The migration of uPA:
PAI-1 complex and intact (—) and reactive-center-
cleaved ($$$) PAI-1 is indicated to the right. The
migration of Mr markers are indicated to the left.
See also Figure S1.
Figure 3. Time Course of Inactivation of PAI-1 by Embelin, as Evalu-
ated by a Chromogenic Assay
PAI-1 (20 nM) was incubated at 37C in the presence of 20 mM embelin. At the
indicated time points, samples of the incubation mixtures were mixed with
equal volumes of 20 nM uPA, either with (solid circles) or without (open circles)
1% BSA, resulting in 10 nM final concentrations of PAI-1 and uPA and a final
concentration of BSA of 0 or 0.5%. After 2 min, the remaining uPA activity was
monitored by addition of the 210 mM of S-2444. The relative PAI-1 activity at
each time point was calculated from the difference in the slope of the lines
relating OD405 to time betweenmixtures with andwithout PAI-1 and expressed
relative to the PAI-1 activity at time zero. The inserted figure is a zoom of the
early times as indicated by the broken lines.
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molecule rather than from direct structural perturbation. In
addition, the crystal packing of the embelin-PAI-1 complex
also agrees well with previously published PAI-1-14-1B struc-
tures (PDB 1DVM and 1B3K), indicating that the presence of
embelin does not impact crystal packing. Surprisingly, well-
defined electron density of only one embelin molecule was
observed in the asymmetric unit. The embelin electron density
(Figure 4D; Table S1) and the omit map (Figure S5) of the
structure were of sufficient quality for unambiguous positioning
of the embelin molecule on the surface of PAI-1.
Embelin is localized in a groove bordered by a helix D, helix F,
b strand 2A, and the loop connecting b strand 1A to hE (Figure 4).
This location is close to the so-called ‘‘flexible joints region’’ (a
helix D and a helix E (Stein and Chothia, 1991) and the ‘‘shutter
region’’ (the central part of b strand 5A and b strand 3A and
the underlying a helix B (Carrell and Stein, 1996). As shown in
Figure 4, the polar, six-member ring of embelin sits in the middle
of a groove forming direct strong contacts (<3.5 A˚) with the side
chain of Asp-95 and the main-chain atoms of residue Thr-93,
both on b strand 2A, andwith residue Tyr-79 on a helix D. In addi-
tion, the embelin head group makes two bifurcated hydrogen
bonds (3.8 A˚ and 5.2 A˚, respectively) with His-143 in the top of
a helix F, and has weaker interactions with Thr-94, and Met-45
on the underlying a helix B. The long aliphatic carbon chain
of embelin, on the other hand, stretches out of the cavity and
participates in interactions with residues including Ser-119 on
the hE-s1A connecting loop and Trp-139 of a helix F.
Even though strong electron density for embelin molecule was
seen in only one of the four PAI-1 molecules (molecule B) in the
asymmetric unit, we did observe weaker electron densities for
the polar embelin ring at the same location in the other three
PAI-1 molecules (Figure S5). The fact that an intact embelin
molecule is observed in only the B molecule in the asymmetric
unit can be attributed to van der Waals crystal contacts between
the embelin aliphatic chain and the neighboring symmetry-
related PAI-1 molecule (residue P111 and the methylene moiety
of residue R115 from molecule D; Figure 4D). These contacts
probably have a dampening effect on the presumably flexible
embelin aliphatic tail. The reduced flexibility would allow us to256 Chemistry & Biology 20, 253–261, February 21, 2013 ª2013 Elseobserve embelin in its preferred binding site in PAI-1. The embe-
lin ring must be presumed to harbor the majority of the binding
energy and to govern its binding-site specificity. These structural
aspects are consistent with the binding data of embelin-related
compounds (Table 1), which show a key role for the ring structure
of embelin and less importance for the aliphatic tail.
The Embelin Binding Site Evaluated by Site-Directed
Mutagenesis
To further validate the details of the interactions of PAI-1 with
embelin, we studied the effect of mutating the residues, which
had been implicated in embelin binding by the X-ray crystal-
structure analysis. We generated five PAI-1 mutants, Y79A,
T94A, D95A, S119A, and H143A, and used the chromogenicvier Ltd All rights reserved
Figure 4. Crystal Structure of PAI-1 in
Complex with Embelin
In all figures, secondary-structure elements of
PAI-1 constituting the binding pocket of embelin
are highlighted as follows: b strands 2A and 1A
and the connecting loop are blue; a helixes D and
F are red; and the underlying a helix B is yellow.
Helixes and b strand numbers are identified. In the
cartoon representation, the remaining strands of
b sheet A are colored green and visible residues
of the RCL connected by a hypothetical sketch
of the unobserved RCL as a dashed line are
highlighted in orange.
(A and B) The PAI-1 molecule shown in cartoon (A)
and surface (B) representation. Embelin is shown
as sticks.
(C) Close-up view of the embelin binding site with
direct contacts shown as cyan dashed lines.
Selected residues of PAI-1 binding to embelin are
given in stick representation with standard atom
(CPK) colors. Tyr-79, located on top of embelin, is
not shown for clarity.
(D) The 2Fo-Fc s-weighted electron density map
wrapping the embelin molecule at a contour level
of 1.0 s is shown as green mesh. Residues from
the crystallographic symmetry-related PAI-1 in
contact with embelin are shown in yellow stick
representation and labeled SYM.
See also Table S1 and Figures S5–S7.
Table 2. The Effect of PAI-1 Mutation on the IC50 of Embelin
Mutants IC50 (mM)
Wild-type 1.62 ± 0.16a
Y79A 3.15 ± 0.67
T94A 1.67 ± 0.15
D95A 15.2 ± 1.87
S119A 2.23 ± 0.38
H143A 12.0 ± 1.80
aIC50 mean value(mM) ± standard deviation, based on at least three
independent experiments.
Chemistry & Biology
Discovery and Structural Basis of PAI-1 Inhibitorassay to evaluate the inhibition of each mutant by embelin. As
shown in Table 2, alanine substitutions of Asp-95 (in b strand
2A) and His-143 (in a helix F) increased the IC50 value about
10-fold. The strong effect of His-143 mutation to alanine may
stem from the bifurcated interaction of the His-143 side chain
with two hydroxyl groups of embelin (Figure 4C). In addition,
the Y79A mutation (in a helix D) caused an approximately
2-fold increase of IC50. No significant changes in IC50 were
observed for mutations T94A and S119A. Thus, the site-directed
mutagenesis results were consistent with the determined crystal
structure.
DISCUSSION
PAI-1 is a potential therapeutic target in several pathophysio-
logical conditions. Therefore, there is great interest in developing
PAI-1 antagonists. Conceivably, there are a number of possible
mechanisms for inactivation of the antiproteolytic action of
PAI-1 (Gils and Declerck, 2004): (1) sterically blocking the initial
formation of the Michae¨lis complex between PAI-1 and its target
proteases; (2) preventing the conformational change in PAI-1
that is associated with complex formation, resulting in cleavage
of PAI-1 as a substrate; or (3) conversion of PAI-1 into an inactive
latent or otherwise inert form. Although the small-moleculeChemistry & Biology 20, 253–261, February 21, 2013antagonist embelin, described here,
does not by itself represent a compound
suitable for in vivo studies, primarily due
to its modest affinity, limited solubility,
strong serum-albumin binding, and
vitronectin competition, this study does
provide structural insight into a small-molecule PAI-1 antagonist using a combination of mechanisms
2 and 3, thus providing an agenda for further development of
PAI-1 antagonists.
The first organochemical PAI-1 antagonist developed was
a diketopiperazine derivative (Bryans et al., 1996). A variety of
related diketopiperazine compounds were developed later
(for a review, see Stoppelli et al., 2008). Various biochemical
analyses showed that the diketopiperazine derivatives induce
a stable, monomeric, inactive PAI-1 conformation that is
different from other known PAI-1 conformations (Egelund et al.,ª2013 Elsevier Ltd All rights reserved 257
Figure 5. Functional Aspects of the Embelin
Binding Site of PAI-1
Color coding and labels of secondary structure
elements are as in Figure 4A.
(A) The figure depicts the well-defined hydrogen-
bond network of the shutter region between
b sheet A and a helix B to which embelin is con-
nected.
(B) The same region in cleaved 14-1B (PDB ID
3CVM) overlaid with embelin from the embelin-
PAI-1 structure. The resulting rearrangement
of the shutter-region hydrogen-bond network is
shown.
See also Figures S6 and S7.
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negatively charged, amphipathic organochemical compounds
of diverse chemical structures were reported to inactivate
PAI-1. Some of these compounds were found to induce PAI-1
substrate behavior within seconds, followed by PAI-1 polymeri-
zation (Egelund et al., 2001; Pedersen et al., 2003). Also, high
concentrations of nonionic detergents induced substrate
behavior and latency transition (for a review, see Stoppelli
et al., 2008). The most potent PAI-1 small-molecule antagonist
isolated to date is a polyphenolic compound, CDE-066 (IC50
10 nM), which acts by blocking the initial formation of the
Michae¨lis complex between PAI-1 and a target protease (Cale
et al., 2010).
Our crystal data, as well as the site-directed mutagenesis
results, clearly show that embelin binds to the groove consti-
tuted by a helixes D and F and b strand 2A. The key residues
involved in the interaction with the antagonist have been defined
as Tyr-79 (a helix D), Asp-95 (b strand 2A), and His-143 (a helix F)
(Figure 4). The location of the binding site is near the binding site
suggested by in silico molecular docking and alanine scanning
mutagenesis with other small-molecule antagonists of PAI-1.
This localization of the binding site is also in good agreement
with the fluorescence-quench data, as the most likely ‘‘reporter’’
tryptophan side chain is Trp-139, situated less than 3.5 A˚ from
embelin (Figure 4) and thus sensing changes in the electronic
environment upon embelin binding. Embelin occupies part of
a small and charged groove. This pocket is sandwiched between
b strand 2A and a helix B and surrounded by residues Asn-167,
Thr-93, Thr-94, Asp-95, Tyr-37, Gly-38, and Ser-41 (pocket 1 in
Figure S6). Interestingly, an even larger and deeper pocket
nearby is not occupied to any significant extent by embelin.
This is a larger, hydrophobic pocket surrounded by a helices
A, B, and D and defined by residues Ala-12, Met-62, Phe-64,
Leu-75, Tyr-37, Ala-40, and Ser-41 (pocket 2 in Figure S6). The
two pockets are separated by residue Ser-41. These two
pockets represent interesting areas to target in future struc-
ture-based studies geared toward development of PAI-1 antag-
onists, and they may be utilized by some previously developed
inhibitors.
Using biochemical methods, we showed that the inactivation
of PAI-1 by embelin follows themechanism previously described
for a group of negatively charged small-molecule antagonists258 Chemistry & Biology 20, 253–261, February 21, 2013 ª2013 Elseof PAI-1 (Egelund et al., 2001; Pedersen et al., 2003). Such an
inactivation mechanism includes a fast reversible step where
embelin induces PAI-1 substrate behavior, followed by a slow
irreversible induction of the PAI-1 inactive form. A shift of b strand
3A and b strand 2A away from b strand 5A and closer to a helix D
and a helix E is necessary to make space for the incoming RCL
during reaction of serpins with target proteases. During sheet
opening, b strands 3A and 5A slide apart over the underlying
a helix B. The shutter region (Carrell and Stein, 1996), underlying
b sheet A, contains a complicated hydrogen-bonding network,
which is rearranged during RCL insertion (Figure 5). Accordingly,
amino acid substitutions in the shutter region affect PAI-1
latency transition and tendency to substrate behavior (Hansen
et al., 2001). In active PAI-1-14-1B, Gln-322, Asn-167, Asp-95,
and Ser-41 are connected by hydrogen bonds, whereas in
cleaved PAI-1-14-1B, Gln-322 is hydrogen-bonded to Ser-35,
while Asn-167 forms hydrogen bonds to Asp-95 and Ser-41 (Fig-
ure 5). A main contact between embelin and PAI-1 is the strong
bifurcated hydrogen bonds to Asp-95 (Figure 4). Moreover, the
localization of the polar ring of embelin seen in the complex
between embelin and native PAI-1-14-1B is not compatible
with binding after RCL insertion and b sheet A expansion, as
this position is then occupied by b strand 2A. Therefore, we
propose that embelin fixes b strand 2A to the neighboring
a helixes, D and F. Embelin thereby may delay the RCL insertion
into b strand A that is a prerequisite for translocation of the
protease to the opposite pole of the serpin and subsequent
covalent complex formation (Dupont et al., 2009; Huntington,
2006). The protease will thus be allowed time to complete the
catalytic cycle, resulting in the cleavage of PAI-1 as a substrate.
Thus, our crystal structure is fully compatible with embelin-
induced PAI-1 substrate behavior. Also, the observed crystal
lattice contacts between the neighboring molecule at b sheet A
suggests that the facilitated crystallization in the presence of em-
belin (and the second, irreversible inactivation step) may involve
a ‘‘strand 7A polymerization’’ (Sharp et al., 1999).
Our described binding site and antagonistic mechanism
may very well be generalized to several other small-molecule
antagonists of PAI-1, which, based on data from competition
with monoclonal antibodies with known epitopes, site-directed
mutagenesis, and molecular modeling, bind in the same area
(Bjo¨rquist et al., 1998; Egelund et al., 2001; Gorlatova et al.,vier Ltd All rights reserved
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agreement with the fact that the antagonistic action of embelin
and this group of compounds is rivaled by vitronectin, having
an adjacent binding site encompassing residues in b strands
1A and 2A and a helix F (Jensen et al., 2002; Zhou et al., 2003).
Embelin is a natural product found in the fruit of the Embelia
ribes Burm plant (Myrsinaceae) and has been shown to have
antitumor (Reuter et al., 2010) and antidiabetes (Mahendran
et al., 2010) properties. Recently, molecular targets of embelin
that contribute to its anticancer effect have been shown to
include X-chromosome-linked inhibitor-of-apoptosis protein
(Nikolovska-Coleska et al., 2004) and nuclear factor-kB (Ahn
et al., 2007). These observations suggest that embelin has
multiple targets. In order to obtain more knowledge on the
specificity of embelin’s action toward PAI-1, we tested embelin
binding to PAI-2 (SERPINB2) and PN-1, both closely related
serpins able to inhibit uPA. We found that embelin inhibited
PN-1 with an IC50 more than 40-fold that with which it inhibited
WT PAI-1, and that it did not inhibit the activity of PAI-2, even
at a concentration of 100 mM. We examined the area in the
PAI-2 crystal structure (PDB 1BY7; Harrop et al., 1999) that
corresponds to the binding site in PAI-1, and found, in agree-
ment with the binding data, that the groove is too shallow and
that the neighboring PAI-2 residues differ from those of PAI-1
to an extent that it is impossible to accommodate an embelin
molecule at this pocket (Figure S7). These data suggests that
embelin is specific enough to discriminate between structurally
similar serpins. Moreover, because PAI-1 also plays an impor-
tant role in tumor metastasis (Andreasen, 2007) and is currently
recognized as the most extensively validated biological prog-
nostic factor in breast cancer (Harris et al., 2007), our study
may expand the understanding of the mechanism behind the
potential anticancer action of embelin.
In summary, our work provides the structural insights into the
mechanism of PAI-1 antagonism by a small-molecule antago-
nist. Such structural information will facilitate further design
and development of highly efficacious PAI-1 antagonists.SIGNIFICANCE
We report the structural characterization of a small-mole-
cule antagonist of PAI-1. This work provides structural clues
to answering the long-standing questions on PAI-1 antago-
nism: What is a suitable binding site in PAI-1? How can
a small molecular antagonist modulate PAI-1? These results
will facilitate the design and development of future PAI-1
antagonists.EXPERIMENTAL PROCEDURES
Screening of Natural Product Library
To identify small molecules with anti-PAI-1 activity, we screened a natural
compound library, which consists of 1,600 bioactive compounds isolated
from various traditional Chinese herbal medicines. In this screening, a chromo-
genic assay (Egelund et al., 2001) was used to measure the inhibitory activities
of small molecules against PAI-1. Briefly, the compounds were preincubated
with PAI-1-14-1B for 10 min, followed by the addition of human uPA. After
an additional 10 min incubation, a chromogenic substrate, S-2444 (L-pyro-
Glu-Gly-Arg-p-nitroaniline HCl, Chromogenix), was added to the mixture.
The final reaction mixture (100 ml) contained 50 mM Tris–HCl, pH 7.4,Chemistry & Biology 20, 253150 mM NaCl, 1% DMSO, 30 nM PAI-1, 40 nM uPA, and 80 mM S-2444.
The activities of the remaining free uPA were then measured by the initial
velocity of cleavage of the chromogenic substrate in a microplate reader (Bio-
Tek Synergy 4) at 405 nm. Compounds with 70% inhibition at 10 mM were
selected for the confirmation screening, and their activities against WT
PAI-1, PAI-2, and PN-1 were also evaluated.
Data were analyzed using OriginPro 7.5 software (OriginLab). The data were
presented as mean ± SD for at least three separate determinations for each
group.
Co-Crystallization of PAI-1-Embelin Complex and Structure
Determination
The PAI-1-14-1B protein (2 mg/ml in buffer A: 50 mM MES, pH 6.1, and 1M
NaCl) was incubated with 200 mM embelin for 30 min at 4C and then dialyzed
against buffer B (20 mM Tris pH 7.4 and 150 mMNaCl). Thereafter, the protein
was reincubated with 200 mM embelin in a final DMSO concentration of 10%
for another 30 min. The protein was then concentrated to 10 mg/ml. Crystals
were grown at 20C using the sitting drop method by mixing equal volumes
of protein solution (10 mg/ml) with a precipitant solution (1.6 M ammonium
sulfate, 0.1 M MES, pH 6.1). The crystals appeared overnight in clustered
thin plates. Single crystals of diffraction quality were finally obtained by streak
seeding method. Diffraction data were collected at BL17U of Shanghai
Synchrotron Radiation Facility at 160C using the precipitant solution
containing 25% glycerol as cryoprotectant. The data was processed and
integrated with HKL2000 (Otwinowski and Minor, 1997). The structure of the
embelin-PAI-1 complex was solved by molecular replacement (Collaborative
Computational Project 4, 1994) using the structure of active PAI-1 (PDB
1B3K; Sharp et al., 1999) as a searching model. The structure was refined
with iterative cycles of manual model building using Coot (Emsley and Cowtan,
2004) and refinement with either Refmac5 (Murshudov et al., 1997) or CNS v1.3
(Brunger, 2007). The quality of the final model was validated with PROCHECK
(Laskowski et al., 1993) and analyzed by PyMol (DeLano, 2003).
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